It’s clear that the clinical team for each study is tasked with creating and managing an individual study budget. The problem is one-off study purchases do not accrue the benefits of volume discounting. Of course, there are numerous and complicated financial arrangements sponsors make with service providers to create optimal rates for clinical trial support – but what about the simple construct of, “buy one shirt, get another for free?”
Long ago, in a land far away, principal investigators were expected to “accrue study subjects” using their network of physician colleagues. Enrolling subjects from one’s patient panel was discouraged as therapeutic misconception might impugn study results. As a result, acceptable enrollment might run from 36 to 60 months or more.
Investigators would commonly send a “Dear Doctor” letter to others within their hospital or to their personal connections. Rarely did these letters produce effective results. Over time, referring physician programs altogether lost value and credibility due to a few commonly held beliefs:
Name something that happens to you five times every waking minute. Give up? It’s advertisements. The average person is exposed to approximately five ad messages every minute, for a total of about 3000 to 5000 advertisements a day. From TV and radio commercials to surfing the web to walking around your local grocery store, the flood of advertisements trying to grab your attention has never been greater. So here are two questions I want you to consider: how many of those ads do you remember and did they motivate you to take action?
Nearly a year ago, we released our first guide on rare disease clinical research. In it, we were looking to address some important questions facing the people who are committed to improving the lives of patients with rare disorders. While much progress has been made, it is critical that those of us in the health care and life sciences industry remain keenly aware of all that’s being done to further research and improve outcomes. In our latest eBook, “Focus 5: Rare Disease Research. What’s Next?” we reached out to industry experts for their insights on this evolving clinical research landscape.
Partnering with advocacy groups is a vital component to any clinical trial outreach effort. The approach to working with advocacy groups has changed in recent years. It is not just about the one connection you may have with one organization. These days it’s about working with the condition community as a whole for one common goal. Advocacy groups often have direct connections to people affected by a condition and can be highly beneficial to enrollment throughout the patient recruitment process.
At the 2015 DIA Annual Meeting this past June there was a lot of talk about how technology is impacting the way we interact with patients, sites, and other key players in the clinical study landscape. When I sat down with three other industry experts to discuss bringing clinical trial practices into the 21st century, I shifted the talk to focus on the forces that drive the way we communicate with patients and with each other within our industry. Furthermore, how can we look at today’s trends to better predict the future of patient recruitment and engagement?
Topics: Patient Recruitment
Pew Research Center indicates that 87 percent of Americans are using the Internet regularly. With social and digital media becoming ever-more prevalent, it makes sense that within the clinical trial industry, researchers are now looking to it as a way to control some of the escalating R&D costs and make the process more patient-centric.
As we discussed in part I of our blog series on adaptive patient recruitment, the rare disease community is constantly striving to invest in developing new treatments. While there is a huge unmet need in this area, there are recruitment tactics that effectively provide support. Beyond the introduction of an early support program, which Jaime Cohen discussed in our previous post, there are additional strategies that can assist in higher recruitment numbers for rare disease. In part II of our series on rare disease we explore further.
The average person spends nearly 4.4 hours of leisure time in front of screens each day. People are online, on their phones or using their tablets in increasing amounts. Given this statistic, it seems natural for there to be a shift from native advertising to content marketing. It’s best to reach consumers where they already are and to push relevant content to them directly to pique interest.
We know that social media usage is up year-over-year across all ages, but how is it being put to use for clinical research? On June 11th I had the pleasure of participating in a social media forum hosted by MassBio with PatientsLikeMe, Biogen and Boston Children’s Hospital. It was an eye opening discussion that looked at the use of social media within clinical trials from the varying perspectives of advocacy groups, IRBs and pharmaceutical companies, each with different goals in mind and facing their own set of unique challenges.